Patents by Inventor Jon Marc Wigginton
Jon Marc Wigginton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230312756Abstract: The present invention is directed in part to dosing regimens for administering a PD-1×CTLA-4 bispecific molecule for the treatment of cancer, and other conditions. The invention is directed in part to the use of such molecules, and to the use of pharmaceutical compositions and pharmaceutical kits that contain such molecules and that facilitate the use of such dosing regimens in the treatment of cancer or to stimulate immune cells.Type: ApplicationFiled: July 23, 2021Publication date: October 5, 2023Inventors: Bradley James SUMROW, Ezio BONVINI, Sharad SHARMA, Jon Marc WIGGINTON, Alexey Yevgenyevich BEREZHNOY
-
Publication number: 20230226206Abstract: The present invention is directed to dosing regimens for administering a humanized anti-B7-H3 antibody conjugated to at least one duocarmycin moiety (a “B7-H3-ADC”) for the treatment of cancer, particularly a cancer associated with expression of B7-H3. The invention particularly concerns the use of such B7-H3-ADC optionally in combination with a PD-1 binding molecule for the treatment of cancer. The invention particularly concerns the use of such B7-H3-ADC and an anti-PD-1 antibody or a PD-1 X LAG-3 bispecific molecule. The invention is directed to the use of such molecules, and to the use of pharmaceutical compositions and pharmaceutical kits that contain such molecules and that facilitate the use of such dosing regimens in the treatment of cancer.Type: ApplicationFiled: May 10, 2021Publication date: July 20, 2023Inventors: Gerry Chester BOHAC, Deryk LOO, Juniper A. SCRIBNER, Jon Marc WIGGINTON
-
Publication number: 20230056230Abstract: The present invention is directed to regimens for administering one or more Antibody-Based Molecules that bind PD-1 or PD-L1, and LAG-3 (e.g, a PD-1×LAG-3 bispecific molecule) alone, or in combination with an Antibody-Based Molecule that binds a Tumor Antigen (TA) for the treatment of cancer. The invention particularly concerns the use of such regimens in conjunction with PD-1×LAG-3 bispecific molecules. The invention is directed to the use of such molecules, and to the use of pharmaceutical compositions and pharmaceutical kits that contain such molecules and that facilitate the use of such dosing regimens in the treatment of cancer.Type: ApplicationFiled: December 18, 2020Publication date: February 23, 2023Applicant: MacroGenics, Inc.Inventors: Bradley James Sumrow, Ross La Motte-Mohs, Jon Marc Wigginton, Ezio Bonvini, Paul A. Moore, Scott Koenig, Xiaoyu Zhang
-
Publication number: 20220213203Abstract: The present invention is directed to a dosing regimen for administering a CD 123×CDS bispecific diabody to patients with a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The present invention is also directed to a dosing regimen for administering a CD 123×CDS bispecific diabody in combination with a molecule capable of binding PD-1 or a natural ligand of PD-1 (a “PD-1 or PD-1 ligand binding molecule”) to patients with a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The invention particularly concerns the use of such regimens for administering the sequence-optimized CD 123×CDS bispecific diabody, “DART-A,” which is capable of simultaneous binding to CD 123 and CDS.Type: ApplicationFiled: April 8, 2020Publication date: July 7, 2022Applicant: MacroGenics, Inc.Inventors: Jan Kenneth Davidson, Ian Lent, Krishnan Sampathkumar, Ralph Froman Alderson, Ross La Motte-Mohs, Jon Marc Wigginton
-
Publication number: 20220204625Abstract: The present invention is directed to a combination therapy involving the administration of a first molecule that specifically binds to human B7-H3 and a second molecule that that specifically binds to human PD-1 to a subject for the treatment of cancer and/or inflammation. The invention also concerns pharmaceutical compositions that comprise a first molecule that specifically binds to human B7-H3 and a second molecule that specifically binds to human PD-1 that are capable of mediating, and more preferably enhancing, the activation of the immune system against cancer cells that are associated with any of a variety of human cancers. The invention also relates to the use of such pharmaceutical compositions to treat cancer and other diseases in recipient subjects.Type: ApplicationFiled: September 20, 2021Publication date: June 30, 2022Applicant: MacroGenics, Inc.Inventors: James Vasselli, Jon Marc Wigginton, Ezio Bonvini, Scott Koenig
-
Publication number: 20220041725Abstract: This invention relates to a pharmaceutical composition that comprises a first molecule that specifically binds HER2/neu and a second molecule that specifically binds a cell-surface receptor (or its ligand) that is involved in regulating an immune checkpoint (or the ligand thereof). The invention particularly relates to the embodiment wherein the second molecule binds to PD-1. The invention also relates to the use of such pharmaceutical compositions to treat cancer and other diseases.Type: ApplicationFiled: June 18, 2021Publication date: February 10, 2022Applicant: MacroGenics, Inc.Inventors: Jon Marc Wigginton, Naimish Bharat Pandya, Robert Joseph Lechleider, Scott Koenig, Ezio Bonvini
-
Patent number: 11174315Abstract: The present invention is directed to a combination therapy involving the administration of a first molecule that specifically binds to human B7-H3 and a second molecule that specifically binds to human PD-1 to a subject for the treatment of cancer and/or inflammation. The invention also concerns pharmaceutical compositions that comprise a first molecule that specifically binds to human B7-H3 and a second molecule that specifically binds to human PD-1 that are capable of mediating, and more preferably enhancing, the activation of the immune system against cancer cells that are associated with any of a variety of human cancers. The invention also relates to the use of such pharmaceutical compositions to treat cancer and other diseases in recipient subjects.Type: GrantFiled: October 6, 2016Date of Patent: November 16, 2021Assignee: MacroGenics, Inc.Inventors: James Vasselli, Jon Marc Wigginton, Ezio Bonvini, Scott Koenig
-
Patent number: 11078279Abstract: This invention relates to a pharmaceutical composition that comprises a first molecule that specifically binds HER2/neu and a second molecule that specifically binds a cell-surface receptor (or its ligand) that is involved in regulating an immune checkpoint (or the ligand thereof). The invention particularly relates to the embodiment wherein the second molecule binds to PD-1. The invention also relates to the use of such pharmaceutical compositions to treat cancer and other diseases.Type: GrantFiled: June 9, 2016Date of Patent: August 3, 2021Assignee: MacroGenics, Inc.Inventors: Jon Marc Wigginton, Naimish Bharat Pandya, Robert Joseph Lechleider, Scott Koenig, Ezio Bonvini
-
Publication number: 20210061911Abstract: The present invention is directed to a dosing regimen for administering a CD123×CD3 bi-specific monovalent diabody to patients with a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The invention particularly concerns the use of such a regimen for the sequence-optimized CD 123×CD3 bi-specific monovalent diabody “DART-A,” that is capable of simultaneous binding to CD 123 and CD3.Type: ApplicationFiled: September 7, 2017Publication date: March 4, 2021Applicant: MacroGenics, Inc.Inventors: Jon Marc Wigginton, Ralph Froman Alderson, Robert Joseph Lechleider
-
Publication number: 20200255524Abstract: The present invention is directed to a combination therapy for the treatment of cancer and pathogen-associated diseases, that comprises the administration of: (I) a molecule (e.g., a diabody, an scFv, an antibody, a TandAb, etc.) capable of binding PD-I or a natural ligand of PD-I, and (2) a molecule (e.g., a diabody, a BiTe, a bispecific antibody, a CAR, etc.) capable of mediating the redirected killing of a target cell (e.g., a cancer cell or a pathogeninfected cell, etc.) expressing a Disease Antigen. The invention particularly concerns the embodiment in which the molecule capable of mediating the redirected killing of the target cell is a bispecific binding molecule that comprises a first epitope-binding site capable of immuno specifically binding an epitope of a cell surface molecule of an effector cell and a second epitope-binding site that is capable of immuno specifically binding an epitope of such target cells.Type: ApplicationFiled: June 6, 2017Publication date: August 13, 2020Inventors: Ezio Bonvini, Scott Koenig, Leslie S. Johnson, Paul A. Moore, Ralph F. Alderson, Jon Marc Wigginton
-
Publication number: 20200095322Abstract: Methods of treatment of cancer with antibodies and antibody fragments that bind to PD-1 are disclosed.Type: ApplicationFiled: June 18, 2019Publication date: March 26, 2020Inventors: Mark Cornfeld, Naimish Bharat Pandya, Jon Marc Wigginton, Ross La Motte-Mohs, Bradley James Sumrow
-
Publication number: 20190389952Abstract: The present invention is directed to a combination therapy involving the administration of a first molecule that specifically binds to human B7-H3 and a second molecule that that specifically binds to human PD-1 to a subject for the treatment of cancer and/or inflammation. The invention also concerns pharmaceutical compositions that comprise a first molecule that specifically binds to human B7-H3 and a second molecule that specifically binds to human PD-1 that are capable of mediating and more preferably enhancing, the activation of the immune system against cancer cells that are associated with any of a variety of human cancers. The invention also relates to the use of such pharmaceutical compositions to treat cancer and other diseases in recipient subjects.Type: ApplicationFiled: October 6, 2016Publication date: December 26, 2019Applicant: MacroGenics, Inc.Inventors: James Vasselli, Jon Marc Wigginton, Ezio Bonvini, Scott Koenig
-
Publication number: 20190322741Abstract: The present invention is directed to methods for using bispecific binding molecules that possess a binding site specific for an epitope of CD32B and a binding site specific for an epitope of CD79B, and are thus capable of simultaneous binding to CD32B and CD79B. The invention particularly concerns such molecules that are bispecific antibodies or bispecific diabodies (and especially such diabodies that additionally comprise an Fc Domain). The invention is directed to the use of such molecules, and to the use of pharmaceutical compositions that contain such molecules in the treatment of inflammatory diseases or conditions.Type: ApplicationFiled: June 6, 2017Publication date: October 24, 2019Applicant: MacroGenics, Inc.Inventors: Wei Chen, Paul A. Moore, Naimish Bharat Pandya, Ezio Bonvini, Jon Marc Wigginton
-
Publication number: 20180298100Abstract: This invention relates to a pharmaceutical composition that comprises a first molecule that specifically binds HER2/neu and a second molecule that specifically binds a cell-surface receptor (or its ligand) that is involved in regulating an immune checkpoint (or the ligand thereof). The invention particularly relates to the embodiment wherein the second molecule binds to PD-1. The invention also relates to the use of such pharmaceutical compositions to treat cancer and other diseases.Type: ApplicationFiled: June 9, 2016Publication date: October 18, 2018Applicant: MacroGenics, Inc.Inventors: Jon Marc Wigginton, Naimish Bharat Pandya, Robert Joseph Lechleider, Scott Koenig, Ezio Bonvini
-
Publication number: 20130156768Abstract: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.Type: ApplicationFiled: August 25, 2011Publication date: June 20, 2013Applicant: Bristol-Myers Squibb CompanyInventors: Maria Jure-Kunkel, Jon Marc Wigginton, Ashok Kumar Gupta